AngioDynamics Reports Settlement Of All Patent Litigation With C.R. Bard
Portfolio Pulse from Benzinga Newsdesk
AngioDynamics has settled all patent litigation with C.R. Bard, a BD company. The settlement includes a one-time payment of $7 million from AngioDynamics to BD, with $3 million paid immediately and the rest over 12 months. Additionally, AngioDynamics will make minimum annual payments of $2.5 million to BD through February 2029, with potential extra payments based on sales of AngioDynamics' port products.
April 01, 2024 | 9:32 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AngioDynamics settles patent litigation with BD, involving a $7M payment and future annual payments. This could impact its financials short term.
The immediate and future financial commitments to BD could strain AngioDynamics' cash flow and financial resources in the short term, potentially impacting its stock price negatively.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
BD settles patent litigation with AngioDynamics, receiving a $7M payment and future annual payments, potentially boosting its financial position.
The settlement provides BD with a one-time payment and a steady stream of income through 2029, which could positively influence its financial health and potentially its stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70